Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes.

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Brigham and Women's Hospital
Study ID
NCT07619508
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tirzepatide — DRUG
    Initiation of tirzepatide described in electronic health records is used as the exposure.
  • Semaglutide — DRUG
    Initiation of injectable semaglutide described in electronic health records is used as the reference.

Study Details

Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Key Dates

Start date
Feb 10, 2026
Status verified
May 2026
Primary completion
Jun 1, 2026
Completion
Jun 1, 2026

Study Design

Enrollment
100,000 participants (estimated)

Arms

  • Arm: Tirzepatide
    Exposure group
  • Arm: Injectable semaglutide
    Reference group

Primary Outcome Measure

Composite of all-cause mortality, myocardial infarction, or stroke. [ Time Frame: 1 day after prescription fill of exposure or comparator until outcome, end of data, end of study period, death, discontinuation (45 day grace, risk-window), nursing home admission, augmentation/additional exposure or switch to comparator or other GLP1-RA ]

Locations (1)

FacilityCityStateZIPSite coordinators
Brigham and Women's HospitalBostonMassachusetts02120-

Find similar trials in Boston, MA

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Brigham and Women's Hospital· Boston, MA

Related Studies